Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Human induced pluripotent stem cells--from mechanisms to clinical applications

Drews, K., Jozefczuk, J., Prigione, A., & Adjaye, J. (2012). Human induced pluripotent stem cells--from mechanisms to clinical applications. Journal of Molecular Medicine-JMM, 90(7), 735-745. doi:10.1007/s00109-012-0913-0.

Item is

Dateien

einblenden: Dateien
ausblenden: Dateien
:
Drews.pdf (Verlagsversion), 289KB
Name:
Drews.pdf
Beschreibung:
-
OA-Status:
Sichtbarkeit:
Öffentlich
MIME-Typ / Prüfsumme:
application/pdf / [MD5]
Technische Metadaten:
Copyright Datum:
-
Copyright Info:
© 2012 Springer, Part of Springer Science+Business Media
Lizenz:
-

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Drews, Katharina1, Autor           
Jozefczuk, Justyna1, Autor           
Prigione, Alessandro1, Autor           
Adjaye, James1, Autor           
Affiliations:
1Molecular Embryology and Aging (James Adjaye), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479654              

Inhalt

einblenden:
ausblenden:
Schlagwörter: Cell Differentiation Epigenesis, Genetic Genomic Instability Humans Induced Pluripotent Stem Cells/cytology/*metabolism Mitochondria/metabolism Regenerative Medicine Toxicity Tests
 Zusammenfassung: Human pluripotent stem cells hold great promise for basic research and regenerative medicine due to their inherent property to propagate infinitely, while maintaining the potential to differentiate into any given cell type of the human body. Since the first derivation in 1998, pluripotent human embryonic stem cells (ESCs) have been studied intensively, and although these cells provoke ethical and immune rejection concerns, translation of human ESC research into the clinics has been initiated. The generation of embryonic stem cell-like human induced pluripotent stem cells (iPSCs) from somatic cells by virus-mediated overexpression of distinct sets of reprogramming factors (OCT4, SOX2, KLF4, and c-MYC, or OCT4, SOX2, NANOG, and LIN28) in 2007 has opened up further opportunities in the field. While circumventing the major disputes associated with human ESCs, iPSCs offer the same advantages and, in addition, new perspectives for personalized medicine. This review summarizes technical advances toward the generation of potentially clinically relevant human iPSCs. We also highlight key molecular events underlying the process of cellular reprogramming and discuss inherent features of iPSCs, including genome instability and epigenetic memory. Furthermore, we will give an overview of particular envisaged human iPSC applications and point out which improvements are yet to come and what has been achieved so far.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2012-05-302012-07
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: DOI: 10.1007/s00109-012-0913-0
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Journal of Molecular Medicine-JMM
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Berlin : Springer
Seiten: - Band / Heft: 90 (7) Artikelnummer: - Start- / Endseite: 735 - 745 Identifikator: ISSN: 0946-2716
CoNE: https://pure.mpg.de/cone/journals/resource/954926989131